Both incidence of tumor cells and tumor volume in the bone marrow were reduced remarkably after simultaneous treatment with TβRI-KI even though TβRI-KI treatment alone was only moderately effective in reducing bone metastasis incidence and tumor burden. This evidence concerns the gene PSME3 and neoplasm.